TC BioPharm (Holdings) plc American Depositary Shares - TCBP STOCK NEWS

TC BioPharm (NASDAQ: TCBP) has announced significant progress in its ACHIEVE Phase 2b clinical trial for TCB008, an allogeneic gamma-delta T cell therapy for cancer. The trial, focusing on patients with AML or MDS/AML, has reached a important milestone with the first patient completing the full dose regimen of approximately one billion cells. Importantly, no TCB008-related adverse events have been observed in any of the restart patients.

Key highlights include:

• 6 patients received a second dose
• 3 patients received a third dose
• 1 patient received a fourth dose
• 3 more patients expected to complete the full regimen by September's end

The company anticipates enrolling 24 patients in Cohort A and expects to announce a full data set, including primary and secondary endpoints, in the first half of 2025.

TC BioPharm (NASDAQ: TCBP) announces significant progress in its ACHIEVE Phase 2b clinical trial for TCB008, an allogeneic gamma-delta T cell therapy for cancer. The first patient has completed the full dose regimen, receiving approximately one billion cells across four doses, with no drug-related adverse events observed. This milestone supports the safety profile of TCB008 and the study's safety objectives.

Key updates include:

• 6 patients received a second dose
• 3 patients received a third dose
• 1 patient received all four doses
• 3 more patients expected to complete the full regimen by September's end

The ACHIEVE trial aims to enroll 24 patients in Cohort A, with 14 initially receiving TCB008. Bryan Kobel, CEO of TC BioPharm, expressed satisfaction with the progress and safety profile. The company anticipates releasing a full data set, including primary and secondary endpoints, in the first half of 2025.

TC BioPharm (NASDAQ: TCBP) has announced plans to initiate Proof of Concept preclinical studies for its lead therapeutic TCB 008 in the treatment of monkeypox. TCB008 is an allogeneic unmodified cell therapy composed of activated and expanded gamma delta T (GDT) cells. The company aims to partner with a leading Infectious Disease Center or University to rapidly advance these studies.

CEO Bryan Kobel highlighted the potential of gamma delta t-cells in mounting a successful immune response against viral infections. TCBP sees this as an opportunity to expand the therapeutic applications of TCB008, particularly in rapid response to aggressive viral infections. The company believes its frozen/thawed product could potentially prevent death, reduce extended viral infection, and help contain the spread of infectious diseases like monkeypox.

TC BioPharm (NASDAQ: TCBP), a clinical stage biotechnology company developing allogeneic gamma-delta T cell therapies, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event will take place from September 9-11, 2024 in New York City, with both in-person and virtual options available. Bryan Kobel, CEO of TC BioPharm, will present an overview of the company's business during the conference. The event will feature over 550 corporate presentations and panels, providing investors with opportunities to learn about various companies and schedule individual meetings with management teams.

TC BioPharm (NASDAQ: TCBP) has announced significant progress in its ACHIEVE Phase 2b trial for TCB008, a potential monotherapy for blood cancers. The company has dosed 6 patients at a higher dose level, with 5 patients receiving their second dose and 2 patients receiving their third dose. Each 5mL dose contains up to 230 million gamma delta T cells, with patients expected to receive approximately 1 billion cells over four doses.

The trial's rapid progression and strong enrollment reflect clinician interest in TCB008. TCBP has implemented process improvements and protocol amendments, resulting in improved patient recruitment and retention. The company is prepared to continue executing its clinical trial plans for ACHIEVE and ACHIEVE2 through 2024 and into 2025, alongside expanded manufacturing capabilities.

TC BioPharm (NASDAQ: TCBP) has successfully closed its upsized $6.0 million public offering. The offering included 6,000,000 American Depository Shares (ADSs) or pre-funded warrants, along with Series H warrants to purchase up to 6,000,000 ADSs at a combined price of $1 per ADS. The Series H Warrants have an exercise price of £0.76 per ADS and will expire in one year. Each ADS represents 200 ordinary shares of the company.

The net proceeds will be used to support TC BioPharm's upcoming clinical trial on relapse/refractory Acute Myeloid Leukemia, increase market awareness, and cover operating expenses and working capital. This offering was made through a registration statement on Form F-1 declared effective by the SEC on August 28, 2024.

TC BioPharm (NASDAQ: TCBP) has been granted a European patent for the use of modified gamma delta cells in treating cancer and viral indications. This patent expands TCBP's portfolio and aligns with their commercial strategy. CEO Bryan Kobel emphasized the company's focus on TCB008 applications while developing future high-value gamma delta assets for indications like solid tumors.

Kobel highlighted the potential of modified gamma delta t-cells to outperform current CAR and modified t-cells in terms of safety and efficacy. The patent protection is seen as creating a competitive advantage and adding value in potential acquisition scenarios.

TC BioPharm (NASDAQ: TCBP) has regained compliance with Nasdaq's Minimum Stockholders' Equity Requirement, maintaining its listing on the Nasdaq Global Select Market. The company, which develops allogeneic gamma-delta T cell therapies, had received a non-compliance notification on May 24, 2024, based on its March 31, 2024 financial position. Despite Nasdaq's concerns about potential future non-compliance due to historical burn rate, TC BioPharm was granted a hearing and subsequently given until August 15, 2024, to meet the requirement. The company believes it has achieved compliance through the closing of transactions outlined in a Purchase Agreement.

TC BioPharm (NASDAQ: TCBP), a clinical stage biotechnology company, has closed a $2.0 million public offering of 2,000,000 American Depository Shares (ADSs) or pre-funded warrants, along with Series G Warrants. The offering was priced at $1 per ADS with associated warrants. Series G Warrants have an exercise price of £0.78 per ADS and will expire in one year. The company plans to use the net proceeds to support its upcoming clinical trial on relapse/refractory Acute Myeloid Leukemia, as well as for continuing operating expenses and working capital. This offering was made through a registration statement on Form F-1 declared effective by the SEC on August 12, 2024.